EMG
TCRT icon

Ellington Management Group’s Alaunos Therapeutics TCRT Stock Holding History

Ellington Management Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-89
Closed -$73K – 698
2016
Q2 		$73K Buy
+89
New +$96.9K 0.1% 230
2016
Q1 		– Sell
-476
Closed -$593K – 693
2015
Q4 		$593K Buy
+476
New +$787K 0.21% 80
2015
Q2 		– Sell
-179
Closed -$290K – 873
2015
Q1 		$290K Buy
+179
New +$265K 0.06% 472

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ellington Management Group's TCRT Position: Q3 2016 in Review

Ellington Management Group sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 89 shares — an estimated $73K sold.

Ellington Management Group first reported a position in TCRT in Q1 2015 and held it in 3 quarters. The position peaked at $593K in Q4 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Ellington Management Group reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Ellington Management Group sold 89 Alaunos Therapeutics shares in Q3 2016, an estimated $73K.
  • Ellington Management Group first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 3 quarters.
  • Ellington Management Group's Alaunos Therapeutics position peaked at $593K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Ellington Management Group's 13F filing for Q3 2016, filed 14 Nov 2016.